Tourette syndrome Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others

(Albany, United States) As per DelveInsight's assessment, globally, the Tourette syndrome pipeline constitutes 6+ key companies continuously working towards developing 6+ Tourette syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Tourette Syndrome Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Tourette Syndrome NDA approvals (if any), and product development activities comprising the technology, Tourette syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Tourette Syndrome pipeline treatment landscape of the report, click here @ Tourette Syndrome Pipeline- https://www.delveinsight.com/report-store/tourette-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Tourette Syndrome Pipeline Report
• DelveInsight's Tourette Syndrome Pipeline analysis depicts a robust space with 6+ active players working to develop 6+ pipeline treatment therapies.
• The leading Tourette Syndrome Companies working in the market include Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others.
• Promising Tourette Syndrome Pipeline Therapies in the various stages of development include TEV-50717, ABX-1431, Sepranolone, SD-809, Ecopipam, Valbenazine, Aripiprazole Oral Solution, NBI-98854, AZD5213, Pramipexole Immediate Release (IR), Aripiprazole, Dronabinol and Palmitoylethanolamide, and others.
• On June 2023, Asarina Pharma announced a study of phase 2 clinical trials for Sepranolone. The study was an open-label, randomized, multicenter, parallel, Phase 2a study in adolescents and adult patients with Tourette syndrome that aimed to explore the efficacy of Sepranolone as a treatment for Tourette syndrome, by reducing the severity and frequency of tics.
• On July 2023, Emalex Biosciences Inc announced a study of phase 3 clinical trias for Ecopipam Hydrochloride. This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.

Tourette Syndrome Overview
Tourette syndrome (TS) is a hereditary neurologic movement disorder characterized by repetitive motor and vocal tics. Symptoms may include involuntary movement of the extremities, shoulders, and face accompanied by uncontrollable sounds and/or inappropriate words.

To explore more information on the latest breakthroughs in the Tourette Syndrome Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tourette Syndrome Emerging Drugs Profile
• Ecopipam: Emalex Biosciences
• SCI-110: SciSparc

Tourette Syndrome Pipeline Therapeutics Assessment
There are approx. 6+ key companies which are developing the therapies for Tourette syndrome. The Tourette Syndrome companies which have their Tourette syndrome drug candidates in the most advanced stage, i.e. phase II include, Emalex Biosciences.

Request a sample and discover the recent advances in Tourette Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Tourette Syndrome Drugs and Companies
• TEV-50717: Teva Pharmaceutical Inc
• ABX-1431: Abide Therapeutics
• Sepranolone: Asarina Pharma
• SD-809: Auspex Pharmaceuticals Inc
• Ecopipam: Emalex Biosciences Inc.

Tourette Syndrome Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Tourette Syndrome Therapeutics Market include-
Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others.

Dive deep into rich insights for drugs for Tourette Syndrome Pipeline, click here for Tourette Syndrome Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Tourette Syndrome Pipeline Report
• Coverage- Global
• Tourette Syndrome Companies- Emalex Biosciences, Noema Pharma, Asarina Pharma, Teva Pharmaceutical, SciSparc, EuMentis Therapeutics, Synendos Therapeutics, and others.
• Tourette Syndrome Pipeline Therapies- TEV-50717, ABX-1431, Sepranolone, SD-809, Ecopipam, Valbenazine, Aripiprazole Oral Solution, NBI-98854, AZD5213, Pramipexole Immediate Release (IR), Aripiprazole, Dronabinol and Palmitoylethanolamide, and others.
• Tourette Syndrome Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Tourette Syndrome Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/tourette-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Tourette syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Tourette syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Ecopipam: Emalex Biosciences
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. SCI-110: SciSparc
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Tourette syndrome Key Companies
21. Tourette syndrome Key Products
22. Tourette syndrome- Unmet Needs
23. Tourette syndrome- Market Drivers and Barriers
24. Tourette syndrome- Future Perspectives and Conclusion
25. Tourette syndrome Analyst Views
26. Tourette syndrome Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.